SCHEMBL3938541

SCHEMBL3938541

Cc1ccsc1-c1c(C#N)c2nc[nH]c(=O)c2n1CCNc1ncnc2ccccc12

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LDHA P00338 1/20 0.35
LMNA P02545 3/20 0.35
GAA P10253 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
ALPG P10696 1/20 0.35
S1PR2 O95136 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
HTT P42858 4/20 0.34
MAPK1 P28482 2/20 0.34
APP P05067 2/20 0.34
EGFR P00533 2/20 0.34
ABCC1 P33527 2/20 0.33
KDM4E B2RXH2 1/20 0.32
MAPT P10636 1/20 0.32
KMT2A Q03164 1/20 0.32
CYP1A2 P05177 4/20 0.32
CYP3A4 P08684 4/20 0.32
CLK4 Q9HAZ1 4/20 0.32
ALDH1A1 P00352 3/20 0.32
HSD17B10 Q99714 3/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3946001 0.80 HTT (0.38) HTT
SCHEMBL4333817 0.79 HTT (0.38) LDHALMNAGAASMN1; SMN2ALPG
Hydrochloric Acid SCHEMBL3941880 0.79 HTT (0.37) HTT
SCHEMBL3935328 0.78 HTT (0.32) LMNAGAAHTTKDM4EMAPT
SCHEMBL13843282 0.76 L3MBTL1 (0.36) LMNAGAANPSR1HTTKDM4E
SCHEMBL4328679 0.74 PDPK1 (0.37) LDHALMNAGAASMN1; SMN2ALPG
SCHEMBL13783381 0.74 CLK4 (0.39) LMNAGAASMN1; SMN2ALPGHTT
SCHEMBL3939357 0.71 HTT (0.33) HTT
SCHEMBL5982912 0.70 HTT (0.39) LDHALMNAGAASMN1; SMN2ALPG
SCHEMBL13843440 0.70 HTT (0.38) HTTCLK4AURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7528140-B2 Substituted pyrrolo[3,2-d]pyrimidines as glycogen synthase kinase (GSK) inhibitors TEIJIN LIMITED (JP) 2009-05-05 US disclosed
US-7528140-B2 Substituted pyrrolo[3,2-d]pyrimidines as glycogen synthase kinase (GSK) inhibitors TEIJIN LIMITED (JP) 2009-05-05 US disclosed
US-20050277773-A1 Pyrrolopyrimidine derivatives TEIJIN LIMITED (JP) 2005-12-15 US disclosed
EP-1477489-A1 PYRROLOPYRIMIDINE DERIVATIVES TEIJIN LIMITED (JP) 2004-11-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050277773-A1 Pyrrolopyrimidine derivatives GSK3B, GSK3A, GSKIP LDHA 3120/4885LMNA 4532/4885GAA 2655/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.